| pubmed-article:14770084 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:14770084 | lifeskim:mentions | umls-concept:C0027651 | lld:lifeskim |
| pubmed-article:14770084 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:14770084 | lifeskim:mentions | umls-concept:C0033684 | lld:lifeskim |
| pubmed-article:14770084 | lifeskim:mentions | umls-concept:C0042196 | lld:lifeskim |
| pubmed-article:14770084 | lifeskim:mentions | umls-concept:C0677907 | lld:lifeskim |
| pubmed-article:14770084 | lifeskim:mentions | umls-concept:C1510427 | lld:lifeskim |
| pubmed-article:14770084 | lifeskim:mentions | umls-concept:C0205470 | lld:lifeskim |
| pubmed-article:14770084 | lifeskim:mentions | umls-concept:C0205390 | lld:lifeskim |
| pubmed-article:14770084 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:14770084 | lifeskim:mentions | umls-concept:C0936012 | lld:lifeskim |
| pubmed-article:14770084 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:14770084 | lifeskim:mentions | umls-concept:C1522673 | lld:lifeskim |
| pubmed-article:14770084 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:14770084 | pubmed:dateCreated | 2004-2-10 | lld:pubmed |
| pubmed-article:14770084 | pubmed:abstractText | In a phase I/II study, patients with solid metastatic MAGE-3-positive tumors, mainly melanoma, were vaccinated with recombinant MAGE-3 protein combined with the immunologic adjuvant AS02B comprised of MPL and QS21 in an oil-in-water emulsion. The recombinant MAGE-3 protein was made up of a partial sequence of the protein D (ProtD) antigen of Haemophilus influenzae fused to the MAGE-3 sequence. The vaccine was given intramuscularly at 3-week intervals. Patients whose tumors stabilized or regressed after 4 vaccinations received 2 additional vaccinations at 6-week intervals. MAGE-3 and ProtD antibody and cellular immune responses were monitored after vaccination. Ninety-six percent (23/24) of the patients vaccinated with MAGE-3 protein in AS02B adjuvant elicited a significant anti-MAGE-3 IgG antibody response after 4 vaccinations, and all developed anti-ProtD IgG antibodies. For the detection of T-cell activity, total peripheral blood mononuclear cells were restimulated in vitro with MAGE-3- or ProtD-loaded autologous mature dendritic cells. In 30% of the evaluable patients vaccinated with the adjuvanted recombinant protein, IFNgamma production was increased in response to MAGE-3, and 2 patients (14% of evaluable patients) had a concomitant increase in IL-5 production. In 37% and 43% of the patients, respectively, IFNgamma or IL-5 production was increased in response to ProtD. It is concluded that vaccination of advanced cancer patients with MAGE-3 self-antigen in AS02B adjuvant is able to elicit MAGE-3-specific antibody and a T-cell response. | lld:pubmed |
| pubmed-article:14770084 | pubmed:language | eng | lld:pubmed |
| pubmed-article:14770084 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14770084 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:14770084 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14770084 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14770084 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14770084 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14770084 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14770084 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14770084 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14770084 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14770084 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14770084 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14770084 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14770084 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14770084 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14770084 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:14770084 | pubmed:issn | 1524-9557 | lld:pubmed |
| pubmed-article:14770084 | pubmed:author | pubmed-author:BrittenCedrik... | lld:pubmed |
| pubmed-article:14770084 | pubmed:author | pubmed-author:StoterGerritG | lld:pubmed |
| pubmed-article:14770084 | pubmed:author | pubmed-author:KeilholzUlric... | lld:pubmed |
| pubmed-article:14770084 | pubmed:author | pubmed-author:LamersCor H... | lld:pubmed |
| pubmed-article:14770084 | pubmed:author | pubmed-author:BruckClaudine... | lld:pubmed |
| pubmed-article:14770084 | pubmed:author | pubmed-author:VantommeValér... | lld:pubmed |
| pubmed-article:14770084 | pubmed:author | pubmed-author:MarchandMarie... | lld:pubmed |
| pubmed-article:14770084 | pubmed:author | pubmed-author:DantinneChris... | lld:pubmed |
| pubmed-article:14770084 | pubmed:author | pubmed-author:AmraniNoreddi... | lld:pubmed |
| pubmed-article:14770084 | pubmed:author | pubmed-author:PermannePhili... | lld:pubmed |
| pubmed-article:14770084 | pubmed:author | pubmed-author:GheysenDirkD | lld:pubmed |
| pubmed-article:14770084 | pubmed:author | pubmed-author:DelireMarcelM | lld:pubmed |
| pubmed-article:14770084 | pubmed:author | pubmed-author:GuéguenMaryse... | lld:pubmed |
| pubmed-article:14770084 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:14770084 | pubmed:volume | 27 | lld:pubmed |
| pubmed-article:14770084 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:14770084 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:14770084 | pubmed:pagination | 124-35 | lld:pubmed |
| pubmed-article:14770084 | pubmed:dateRevised | 2008-11-21 | lld:pubmed |
| pubmed-article:14770084 | pubmed:meshHeading | pubmed-meshheading:14770084... | lld:pubmed |
| pubmed-article:14770084 | pubmed:meshHeading | pubmed-meshheading:14770084... | lld:pubmed |
| pubmed-article:14770084 | pubmed:meshHeading | pubmed-meshheading:14770084... | lld:pubmed |
| pubmed-article:14770084 | pubmed:meshHeading | pubmed-meshheading:14770084... | lld:pubmed |
| pubmed-article:14770084 | pubmed:meshHeading | pubmed-meshheading:14770084... | lld:pubmed |
| pubmed-article:14770084 | pubmed:meshHeading | pubmed-meshheading:14770084... | lld:pubmed |
| pubmed-article:14770084 | pubmed:meshHeading | pubmed-meshheading:14770084... | lld:pubmed |
| pubmed-article:14770084 | pubmed:meshHeading | pubmed-meshheading:14770084... | lld:pubmed |
| pubmed-article:14770084 | pubmed:meshHeading | pubmed-meshheading:14770084... | lld:pubmed |
| pubmed-article:14770084 | pubmed:meshHeading | pubmed-meshheading:14770084... | lld:pubmed |
| pubmed-article:14770084 | pubmed:meshHeading | pubmed-meshheading:14770084... | lld:pubmed |
| pubmed-article:14770084 | pubmed:meshHeading | pubmed-meshheading:14770084... | lld:pubmed |
| pubmed-article:14770084 | pubmed:meshHeading | pubmed-meshheading:14770084... | lld:pubmed |
| pubmed-article:14770084 | pubmed:meshHeading | pubmed-meshheading:14770084... | lld:pubmed |
| pubmed-article:14770084 | pubmed:meshHeading | pubmed-meshheading:14770084... | lld:pubmed |
| pubmed-article:14770084 | pubmed:meshHeading | pubmed-meshheading:14770084... | lld:pubmed |
| pubmed-article:14770084 | pubmed:meshHeading | pubmed-meshheading:14770084... | lld:pubmed |
| pubmed-article:14770084 | pubmed:meshHeading | pubmed-meshheading:14770084... | lld:pubmed |
| pubmed-article:14770084 | pubmed:meshHeading | pubmed-meshheading:14770084... | lld:pubmed |
| pubmed-article:14770084 | pubmed:meshHeading | pubmed-meshheading:14770084... | lld:pubmed |
| pubmed-article:14770084 | pubmed:meshHeading | pubmed-meshheading:14770084... | lld:pubmed |
| pubmed-article:14770084 | pubmed:meshHeading | pubmed-meshheading:14770084... | lld:pubmed |
| pubmed-article:14770084 | pubmed:meshHeading | pubmed-meshheading:14770084... | lld:pubmed |
| pubmed-article:14770084 | pubmed:meshHeading | pubmed-meshheading:14770084... | lld:pubmed |
| pubmed-article:14770084 | pubmed:meshHeading | pubmed-meshheading:14770084... | lld:pubmed |
| pubmed-article:14770084 | pubmed:meshHeading | pubmed-meshheading:14770084... | lld:pubmed |
| pubmed-article:14770084 | pubmed:meshHeading | pubmed-meshheading:14770084... | lld:pubmed |
| pubmed-article:14770084 | pubmed:articleTitle | Immunologic analysis of a phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors. | lld:pubmed |
| pubmed-article:14770084 | pubmed:affiliation | GlaxoSmithKline Biologicals, Rixensart, Belgium. | lld:pubmed |
| pubmed-article:14770084 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:14770084 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:14770084 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| pubmed-article:14770084 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14770084 | lld:pubmed |
